RNA

RNA

USD

Avidity Biosciences Inc. Common Stock

$69.830+0.050 (0.072%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$69.780

Kõrge

$69.870

Madal

$69.760

Maht

7.06M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

10.3B

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

5.20M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $21.51Praegune $69.830Kõrge $70.51

Seotud uudised

PR Newswire

Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Vaata rohkem
Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights
Analyst Upgrades

TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74

TD Cowen analyst Ritu Baral downgrades Avidity Biosciences from Buy to Hold and lowers the price target from $78 to $74.

Vaata rohkem
TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74
PR Newswire

Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with...

Vaata rohkem
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders
Analyst Upgrades

Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72

Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences from Buy to Neutral and lowers the price target from $75 to $72.

Vaata rohkem
Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
Analyst Upgrades

RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72

RBC Capital analyst Luca Issi downgrades Avidity Biosciences from Outperform to Sector Perform and raises the price target from $61 to $72.

Vaata rohkem
RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

Analyst Upgrades

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.